PPARG and diabetes mellitus: Per the available clinical data for probands with likely pathogenic PPARγ2 variants, 89% (57/64) were diagnosed with diabetes or impaired glucose tolerance, 86% (32/37) were diagnosed before 40 years of age, and 85% patients (11/13) showed an improvement in glucose control after thiazolidinedione therapy.